Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases
暂无分享,去创建一个
K. Nikolaou | T. Seufferlein | D. Zips | D. Thorwarth | S. Boeke | M. Bitzer | R. Hoffmann | S. Gatidis | M. Nachbar | C. Gani | J. Boldt | Sarah Butzer | A. Königsrainer | Laura Uder | Sabrina Baumeister
[1] T. Welzel,et al. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3) , 2022, Radiation oncology.
[2] D. Low,et al. Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis , 2021, Cancer medicine.
[3] B. van Triest,et al. Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac , 2021, Clinical and translational radiation oncology.
[4] C. K. Spindeldreier,et al. Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Tumors: Initial Clinical Experience and Patient-Reported Outcomes , 2021, Frontiers in Oncology.
[5] A. Kishan,et al. Ablative Radiotherapy for Liver Tumors Using Stereotactic MRI-Guidance: A Prospective Phase I Trial. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] L. Dawson,et al. MR-Guided Radiotherapy for Liver Malignancies , 2021, Frontiers in Oncology.
[7] U. Abacıoğlu,et al. Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience , 2021, Radiation oncology journal.
[8] D. Mönnich,et al. Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac – Feasibility, workflow data and patient acceptance , 2020, Clinical and translational radiation oncology.
[9] L. Collette,et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. , 2020, The Lancet. Oncology.
[10] L. Livi,et al. Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and analysis of electron return and stream effects. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] Michael Lock,et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.
[12] Sebastian Klüter,et al. Technical design and concept of a 0.35 T MR-Linac , 2019, Clinical and translational radiation oncology.
[13] Rob H.N. Tijssen,et al. Adaptive radiotherapy: The Elekta Unity MR-linac concept , 2019, Clinical and translational radiation oncology.
[14] M. Scorsetti,et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up , 2018, Radiation oncology.
[15] D. Mönnich,et al. Comparison of treatment plans for a high-field MRI-linac and a conventional linac for esophageal cancer , 2018, Strahlentherapie und Onkologie.
[16] H. Lyng,et al. Potentials and challenges of diffusion-weighted magnetic resonance imaging in radiotherapy , 2018, Clinical and translational radiation oncology.
[17] R. Semrau,et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases , 2018, BMC Cancer.
[18] W. Jackson,et al. Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. , 2017, International journal of radiation oncology, biology, physics.
[19] G G Hanna,et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).
[20] Andrew Jackson,et al. Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. , 2018, International journal of radiation oncology, biology, physics.
[21] Jong Hoon Kim,et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. , 2017, International journal of radiation oncology, biology, physics.
[22] D. Edvardsson,et al. Development and psychometric testing of an instrument to measure the patient’s experience of external radiotherapy: The Radiotherapy Experience Questionnaire (RTEQ) , 2017, Technical innovations & patient support in radiation oncology.
[23] N. Kim,et al. Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). , 2017, Oncology reports.
[24] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[25] J F Fowler,et al. 21 years of biologically effective dose. , 2010, The British journal of radiology.
[26] Anand Mahadevan,et al. Stereotactic body radiation therapy for liver metastases. , 2009, European journal of cancer.
[27] P. Levendag,et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. , 2008, International journal of radiation oncology, biology, physics.
[28] Robert G. Moore,et al. Initial clinical experience , 1997 .
[29] M. Anscher,et al. Hepatic toxicity resulting from cancer treatment. , 1995, International journal of radiation oncology, biology, physics.